Clinical TrialJul 6, 2026, 07:02 AM
Can-Fite BioPharma Completes Enrollment for Phase 3 Psoriasis Study
AI Summary
Can-Fite BioPharma Ltd. announced the completion of enrollment for the first 247 patients in its pivotal Phase 3 study evaluating Piclidenoson for moderate-to-severe plaque psoriasis. The study has now reached the pre-specified interim analysis stage, which will assess efficacy and safety data under a protocol agreed with both the U.S. FDA and the European Medicines Agency (EMA). Results from this analysis are anticipated in Q4 2026 or Q1 2027. Piclidenoson is an oral A3 adenosine receptor agonist with a favorable safety profile, positioning it as a potential new treatment option.
Key Highlights
- Completed enrollment of 247 patients in pivotal Phase 3 study for Piclidenoson.
- Reached pre-specified interim analysis stage for Piclidenoson in psoriasis.
- Interim analysis protocol agreed with both FDA and EMA.
- Results from the interim analysis are expected in Q4 2026/Q1 2027.
- Piclidenoson is an oral A3 adenosine receptor agonist for moderate-to-severe plaque psoriasis.
- Co-primary efficacy objectives include PASI 75 and sPGA 0 or 1 at Week 16.
- Piclidenoson has demonstrated a favorable safety profile in over 1,500 subjects.
Price Impact
More from CANF